{
    "clinical_study": {
        "@rank": "51857", 
        "arm_group": [
            {
                "arm_group_label": "0.3 mg LY2624803", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "3.0 mg LY2624803", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "6.0 mg LY2624803", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "10 mg Zolpidem", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of placebo administered orally in up to 1 of 4 treatment periods."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy\n      people. The study has four treatment periods.  Participants will receive a single dose of\n      LY2624803, another sleeping pill, or placebo in each treatment period. The study will last\n      approximately 1 month for each participant."
        }, 
        "brief_title": "A Study of LY2624803 in Participants With Transient Insomnia", 
        "completion_date": {
            "#text": "November 2008", 
            "@type": "Actual"
        }, 
        "condition": "Transient Insomnia", 
        "condition_browse": {
            "mesh_term": "Sleep Initiation and Maintenance Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Overtly healthy males or females\n\n          -  Women of child-bearing potential, who test negative for pregnancy at the time of\n             enrollment based on a urine pregnancy test and agree to use a reliable method of\n             birth control during the study and for one month following the last dose of study\n             drug\n\n          -  Between the Body Mass Index (BMI) of 19 and 30 kilogram per meter square (kg/m^2),\n             inclusive\n\n          -  Normal bedtime hours, with routine time spent in bed between 6.5 hours and 9 hours\n             each night\n\n          -  Participants whose daily caffeine intake permits maintenance of normal bed time hours\n\n          -  Non response to placebo defined as a Wake After Sleep Onset (WASO) of greater than or\n             equal to 45 minutes, on a 5-hour phase-advanced polysomnography (PSG) screening night\n             after bedtime single-blind placebo administration\n\n          -  Males must agree to use effective barrier contraception during the course of the\n             trial and 3 months later\n\n          -  Participants over 65 years of age, on a stable dose of one medication for lowering\n             cholesterol, triglycerides and/or one medication for lowering blood pressure and/or\n             substitutive hormonal therapy in post menopausal women are allowed provided those\n             treatments have no central effect\n\n          -  Clinical laboratory test results within normal reference range judged to be not\n             clinically significant\n\n          -  Normal sitting blood pressure and pulse rate as determined\n\n          -  Venous access sufficient to allow blood sampling\n\n          -  Are reliable and willing to make themselves available for the duration of the study\n\n          -  Have given written informed consent approved by Lilly and the ethical review board\n             governing the site\n\n        Exclusion Criteria:\n\n          -  Shift workers (those who shifted work within 7 days of any PSG night) or any person\n             who has crossed (or will have crossed) more than one time zone by aircraft within 3\n             days prior to entry\n\n          -  Rhinoconjunctivitis, urticaria or chronic pain severe enough to interfere with sleep\n\n          -  Nocturia that would interfere with sleep assessment\n\n          -  Participants with allergic conjunctivitis or urticaria\n\n          -  Regular napping (greater than (\u2265) 2 daytime naps/week by history)\n\n          -  Symptoms consistent with a sleep disorder or history of same\n\n          -  Sleep disorders detected during the screening night\n\n          -  Evidence of significant active neuropsychiatric disease and in particular evidence of\n             significant medical or psychiatric illness within the past 12 months that could\n             contribute to insomnia\n\n          -  Irregular or altered sleep/wake schedule\n\n          -  Known history of fainting or low blood pressure. History of cranial trauma and loss\n             of consciousness will be discussed prior to including any such participant\n\n          -  Within 3 months of the initial dose of study drug, have received treatment with a\n             drug that has not received regulatory approval for any indication\n\n          -  Participants with postural hypotension at screening\n\n          -  Participants with a history of postural hypotension, loss of consciousness, explained\n             or unexplained syncope or seizure episodes or a family history of seizures. History\n             of a single febrile convulsion is acceptable\n\n          -  Known allergies to LY2624803, Zolpidem or related compounds\n\n          -  Persons who have previously completed or withdrawn from this study or any other study\n             investigating LY2624803\n\n          -  An abnormality in the 12-lead electrocardiogram (ECG) that increases the risks\n             associated with participating in the study\n\n          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,\n             endocrine, hematological, neurocardiogenic or neurological disorders capable of\n             significantly altering the absorption, metabolism, or elimination of drugs; of\n             constituting a risk when taking the study medication; or of interfering with the\n             interpretation of data\n\n          -  Any other condition with in the opinion of the investigator would preclude\n             participation the study\n\n          -  Regular use of known drugs of abuse and/or positive findings on urinary drug\n             screening\n\n          -  Evidence of Human Immunodeficiency Virus (HIV) and/or positive human HIV antibodies\n\n          -  Evidence of hepatitis C and/or positive hepatitis C antibody\n\n          -  Evidence of hepatitis B and/or positive hepatitis B surface antigen\n\n          -  Women with a positive pregnancy test\n\n          -  Women who are lactating\n\n          -  Use of prescription, over the counter or herbal medications that cannot safely be\n             discontinued within 28 days prior to enrollment\n\n          -  Blood donation of more than 500 milliliter (mL) within the last month\n\n          -  History of smoking within the previous 6 months of screening\n\n          -  Participants who have an average weekly alcohol intake that exceeds 28 units per week\n             (males) and 21 units per week (females), or participants unwilling to stop alcohol\n             consumption for the duration of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779830", 
            "org_study_id": "12057", 
            "secondary_id": "I2K-MC-ZZAA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "0.3 mg LY2624803", 
                    "3.0 mg LY2624803", 
                    "6.0 mg LY2624803"
                ], 
                "description": "Administered orally as capsules.", 
                "intervention_name": "LY2624803 - Capsules", 
                "intervention_type": "Drug", 
                "other_name": "Hypnion"
            }, 
            {
                "arm_group_label": "10 mg Zolpidem", 
                "description": "Administered orally as tablets.", 
                "intervention_name": "Zolpidem - Tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered orally as capsules.", 
                "intervention_name": "Placebo - Capsules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered orally as tablets.", 
                "intervention_name": "Placebo - Tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Zolpidem"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rouffach", 
                    "country": "France"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Crossover Study of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to Day 60"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Latency to Persistent Sleep (LPS) with LY2624803 Compared to Placebo", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Day 60"
            }, 
            {
                "measure": "Total Sleep Time (TST) with LY2624803 Compared to Placebo", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Day 60"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}